<DOC>
	<DOCNO>NCT00123149</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety profile epoetin alfa patient anemia chronic disease due rheumatoid arthritis</brief_summary>
	<brief_title>Open-Label Extension Safety Study PROCRIT Patients With Anemia Chronic Disease Due Rheumatoid Arthritis</brief_title>
	<detailed_description>Epoetin alfa analogue erythropoetin , hormone secrete kidney know stimulate red blood cell production . Although epoetin alfa know effective treatment anemia associate chronic kidney disease , information effectiveness long-term safety treatment anemia associate rheumatoid arthritis limit . This 35-week safety study extension 20-week , prospective , randomize , double-blind , placebo-controlled , multi-center study investigate effectiveness epoetin alfa patient anemia chronic disease due rheumatoid arthritis . The study hypothesis long-term safety concern epoetin alfa administer every two week rheumatoid arthritis patient anemia chronic disease . Patients receive epoetin alfa injection ( 40,000 unit ) skin every 2 week 31 week . Doses may adjust depend patient ' hemoglobin level maximum 60,000 unit every 2 week 40,000 unit weekly .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients must sign informed consent Women must postmenopausal least one year , surgically sterile , practice effective method birth control , negative serum pregnancy test Week 1 study Women must breast feeding study period Patients must complete doubleblind ( DB ) study ( PR0333055 ) without miss 4 study visit hemoglobin level less equal 12.9 g/dL Week 20 DB study Uncontrolled hypertension Elective surgery , include joint replacement , anticipated require transfusion extension study period Thromboembolic event doubleblind study include acute myocardial infarction , Cerebrovascular accident and/or transient ischemic attack Deep vein thrombosis and/or pulmonary embolism Uncontrolled psychiatric disease comorbid disease develop worsen since enrollment doubleblind study Planning enrol clinical trial course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Hemoglobin level</keyword>
</DOC>